New Century Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

New Century Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,871	Closed	-$251K	–	280
2024 Q1	$251K	Sell	2,871 -1,851	-39%	-$166K	0.17%	149
2023 Q4	$455K	Buy	+4,722	New	+$418K	0.39%	89

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

New Century Financial Group's BMRN Position: Q2 2024 in Review

New Century Financial Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 2,871 shares — an estimated $251K sold.

New Century Financial Group first reported a position in BMRN in Q4 2023 and held it in 2 quarters. The position peaked at $455K in Q4 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

New Century Financial Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
New Century Financial Group sold 2,871 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $251K.
New Century Financial Group first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 2 quarters.
New Century Financial Group's BioMarin Pharmaceuticals position peaked at $455K in Q4 2023.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on New Century Financial Group's 13F filing for Q2 2024, filed 27 Aug 2024.